60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Monday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ SXTP opened at $1.32 on Monday. The stock has a market capitalization of $3.03 million, a price-to-earnings ratio of -0.13 and a beta of 5.36. 60 Degrees Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $18.36. The stock’s 50 day moving average price is $1.10 and its two-hundred day moving average price is $0.91.

Insider Buying and Selling

In related news, CEO Geoffrey S. Dow bought 35,823 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the completion of the acquisition, the chief executive officer now owns 94,580 shares of the company’s stock, valued at approximately $120,116.60. The trade was a 60.97 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders acquired 66,372 shares of company stock worth $82,410. 10.27% of the stock is owned by insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.